Seasoned healthcare and technology leaders bring critical expertise to guide Autonomize AI’s next stage of growth
Autonomize AI, the pioneer in Agentic AI orchestration for healthcare and life sciences, announced the appointment of Michele Paige and Tamara Elias, MD to its Growth Advisory Board. They join a distinguished group of leaders—including Joan Harvey, Pritesh Gandhi, MD, MPH, Anthony Nguyen, MD, MBA, and Sarah Bezerredi—who are shaping Autonomize’s strategy as the company scales its impact across health plans, providers, and pharmacy benefit management organizations.
Health Technology Insights: Doctivity Health Launches Doctivity AI for Healthcare Growth
Michele Paige brings deep expertise in PBM and pharmacy operations, having led product and digital strategy at Elevance Health’s CarelonRx. Her leadership in specialty pharmacy and affordability initiatives will be critical as Autonomize AI accelerates the expansion of its enterprise AI platform and marketplace of pre-built, pre-trained AI Agents into pharmacy-linked workflows.
Health Technology Insights: DataJoint Raises $4.9 Million to Transform Data Management in Science
Tamara Elias, MD is a seasoned physician executive and former private equity partner with nearly a decade of investment experience. She has led operating and partnership initiatives across health plans, life sciences, and technology companies, including senior roles at Microsoft/Nuance, Merck, Aetna, Becton Dickinson, and McKinsey. Her perspective at the intersection of care delivery, pharma, enterprise technology, and capital strategy will help guide Autonomize AI’s next wave of strategic partnerships and growth.
“Welcoming Michele and Tamara to our Growth Advisory Board reflects our commitment to scaling with precision,” said Ganesh Padmanabhan, CEO of Autonomize AI. “Michele’s track record in PBM innovation and Tamara’s rare combination of success in physician leadership, operator experience, and as a private equity partner gives us both strategic and capital perspective. Their expertise will be invaluable as we build the next phase of Autonomize’s growth.”
The company’s Growth Advisory Board, chaired by Joan Harvey, convenes senior leaders from across the healthcare ecosystem to guide Autonomize AI’s expansion strategy and strengthen its position as the agentic AI platform of choice for leading healthcare enterprises.
Health Technology Insights: ENHERTU Gets FDA Nod for High-Risk Early HER2+ Breast Cancer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
